Axura

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

memantinijev klorid

Available from:

Merz Pharmaceuticals GmbH

ATC code:

N06DX01

INN (International Name):

memantine

Therapeutic group:

Druga zdravila proti demenciji

Therapeutic area:

Alzheimerjeva bolezen

Therapeutic indications:

Zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.

Product summary:

Revision: 27

Authorization status:

Pooblaščeni

Authorization date:

2002-05-17

Patient Information leaflet

                                29
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Merz Pharmaceuticals GmbH
Eckenheimer Landstr. 100
D-60318 Frankfurt/Main
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/02/218/012 14 filmsko obloženih tablet
EU/1/02/218/007 28 filmsko obloženih tablet
EU/1/02/218/001 30 filmsko obloženih tablet
EU/1/02/218/013 42 filmsko obloženih tablet
EU/1/02/218/002 50 filmsko obloženih tablet
EU/1/02/218/008 56 filmsko obloženih tablet
EU/1/02/218/014 98 filmsko obloženih tablet
EU/1/02/218/003 100 filmsko obloženih tablet
EU/1/02/218/009 112 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Serija{številka}
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Axura 10 mg tablete
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
30
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA ZA 42, 50 IN 98 TABLET KOT PRIMARNA OVOJNINA/DEL VEČKRATNEGA
PAKIRANJA (BREZ "BLUE BOX")
1.
IME ZDRAVILA
Axura 10 mg filmsko obložene tablete
memantinijev klorid
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Vsaka filmsko obložena tableta vsebuje 10 mg memantinijevega klorida,
kar ustreza 8,31 mg
memantina.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
42 filmsko obloženih tablet
Sestavni del večkratnega pakiranja se ne sme prodajati ločeno.
50 filmsko obloženih tablet
Sestavni del večkratnega pakiranja se ne sme prodajati ločeno.
98 filmsko obloženih tablet
Sestavni del večkratnega pakiranja se ne sme prodajati ločeno.
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Peroralna uporaba. Pred uporabo preberite navodilo za uporabo.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Upo
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Axura 10 mg filmsko obložene tablete
Axura 5 mg+10 mg+15 mg+20 mg filmsko obložene tablete
Axura 20 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Axura 10 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 10 mg memantinijevega klorida,
kar ustreza 8,31 mg
memantina.
Axura 5 mg+10 mg+15 mg+20 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 5 mg memantinijevega klorida,
kar ustreza 4,15 mg memantina.
Ena filmsko obložena tableta vsebuje 10 mg memantinijevega klorida,
kar ustreza 8,31 mg
memantina.
Ena filmsko obložena tableta vsebuje 15 mg memantinijevega klorida,
kar ustreza 12,46 mg
memantina.
Ena filmsko obložena tableta vsebuje 20 mg memantinijevega klorida,
kar ustreza 16,62 mg
memantina.
Axura 20 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 20 mg memantinijevega klorida,
kar ustreza 16,62 mg
memantina.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložene tablete.
Axura 10 mg filmsko obložene tablete
Bledo rumene do rumene, ovalne filmsko obložene tablete, z razdelilno
zarezo in vtisnjeno številko
"1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
Tableta se lahko deli na enake odmerke.
Axura 5 mg+10 mg+15 mg+20 mg filmsko obložene tablete
5 mg filmsko obložene tablete so bele do belkaste, ovalno
podolgovate, filmsko obložene tablete z
vtisnjeno številko "5" na eni strani in vtisnjeno besedo "MEM" na
drugi strani.
10 mg filmsko obložene tablete so bledo rumene do rumene, ovalne, z
razdelilno zarezo in vtisnjeno
številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi
strani. Tableta se lahko deli na enaki
polovici.
15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalno
podolgovate, filmsko obložene
tablete z vtisnjeno številko "15" na eni strani in vtisnjeno besedo
"MEM" na drugi strani.
20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno
podolgovate, films
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2024
Public Assessment Report Public Assessment Report Bulgarian 05-01-2012
Patient Information leaflet Patient Information leaflet Spanish 26-02-2024
Public Assessment Report Public Assessment Report Spanish 05-01-2012
Patient Information leaflet Patient Information leaflet Czech 26-02-2024
Public Assessment Report Public Assessment Report Czech 05-01-2012
Patient Information leaflet Patient Information leaflet Danish 26-02-2024
Public Assessment Report Public Assessment Report Danish 05-01-2012
Patient Information leaflet Patient Information leaflet German 26-02-2024
Public Assessment Report Public Assessment Report German 05-01-2012
Patient Information leaflet Patient Information leaflet Estonian 26-02-2024
Public Assessment Report Public Assessment Report Estonian 05-01-2012
Patient Information leaflet Patient Information leaflet Greek 26-02-2024
Public Assessment Report Public Assessment Report Greek 05-01-2012
Patient Information leaflet Patient Information leaflet English 26-02-2024
Public Assessment Report Public Assessment Report English 05-01-2012
Patient Information leaflet Patient Information leaflet French 26-02-2024
Public Assessment Report Public Assessment Report French 05-01-2012
Patient Information leaflet Patient Information leaflet Italian 26-02-2024
Public Assessment Report Public Assessment Report Italian 05-01-2012
Patient Information leaflet Patient Information leaflet Latvian 26-02-2024
Public Assessment Report Public Assessment Report Latvian 05-01-2012
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2024
Public Assessment Report Public Assessment Report Lithuanian 05-01-2012
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2024
Public Assessment Report Public Assessment Report Hungarian 05-01-2012
Patient Information leaflet Patient Information leaflet Maltese 26-02-2024
Public Assessment Report Public Assessment Report Maltese 05-01-2012
Patient Information leaflet Patient Information leaflet Dutch 26-02-2024
Public Assessment Report Public Assessment Report Dutch 05-01-2012
Patient Information leaflet Patient Information leaflet Polish 26-02-2024
Public Assessment Report Public Assessment Report Polish 05-01-2012
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2024
Public Assessment Report Public Assessment Report Portuguese 05-01-2012
Patient Information leaflet Patient Information leaflet Romanian 26-02-2024
Public Assessment Report Public Assessment Report Romanian 05-01-2012
Patient Information leaflet Patient Information leaflet Slovak 26-02-2024
Public Assessment Report Public Assessment Report Slovak 05-01-2012
Patient Information leaflet Patient Information leaflet Finnish 26-02-2024
Public Assessment Report Public Assessment Report Finnish 05-01-2012
Patient Information leaflet Patient Information leaflet Swedish 26-02-2024
Public Assessment Report Public Assessment Report Swedish 05-01-2012
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2024
Patient Information leaflet Patient Information leaflet Croatian 26-02-2024

Search alerts related to this product

View documents history